A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study Of Acalabrutinib In Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, And Prednisone (R-CHOP) In Subjects >65 Years With Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
Email for information
Research Start Date
The primary objective of the study is to evaluate the effect of adding acalabrutinib to R-CHOP for progression-free survival in previously untreated non-germinal center diffuse large B-cell lymphoma.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.